Stocks · US
RPRX
XNAS
Royalty Pharma plc Class A Ordinary Shares
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E30.96x
P/B3.69x
P/S9.95x
EPS$1.83
ROE11.93%
ROA4.11%
Dividend yield1.58%
EV/EBITDA19.53x
Debt/Equity1.33
Free cash flow$3.0B
Returns and 52-week range
1W-3.06%
1M-11.76%
3M-3.31%
6M+20.42%
1Y+56.47%
YTD+45.24%
52W high$64.38
52W low$35.23
From 52W high-12.33%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| 퀘스트 다이어그노스틱스 | $25.6B | 24.20 | 3.41 | -3.69% |
| 가단트 헬스 | $25.1B | — | — | +5.75% |
| Roivant Sciences Ltd. Common Shares | $25.8B | — | 6.11 | +1.72% |
| 랩코프 | $25.0B | 24.97 | 2.91 | -4.64% |
| West Pharmaceutical Services, Inc. | $26.5B | 46.94 | 8.87 | +9.61% |
| Incyte Genomics Inc | $23.1B | 14.35 | 3.65 | -11.06% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.